nach oben

Journal of Translational Medicine

Erschienen in:

Open Access 01.12.2018 | Research

Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia

verfasst von: Noemy Starita, Luigi Buonaguro, Franco M. Buonaguro, Maria Lina Tornesello

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2018

Abstract

Background

Squamous cell carcinoma (SCC) of the conjunctiva is a common cancer in Africa mainly associated with solar ultraviolet (UV) exposure and human immunodeficiency virus (HIV) infection. We analyzed the role of HIV on the occurrence of telomerase reverse transcriptase (TERT) promoter mutations among a cohort of conjunctiva neoplasia Ugandan patients.

Methods

Telomerase reverse transcriptase promoter mutations were searched in 72 conjunctiva neoplasia cases, comprising SCC and intraepithelial neoplasia grade 1–3 (CIN1–3), as well as in 53 conjunctiva normal tissues and in 24 HIV-related Kaposi sarcoma.

Results

The average prevalence of TERT promoter mutations in conjunctiva neoplasia was 31.9%. The mutation rates were significantly higher in HIV-positive (31.8% of CIN1 and CIN2, 46.2% of CIN3 and SCC,) than HIV-negative patients (22.2% of CIN1 and CIN2, 13.3% of CIN3 and SCC). Such mutations were rarely identified among HIV-positive conjunctiva controls (3.6%) and never in Kaposi sarcoma lesions. The most frequent variations were the hot spots − 124G>A and − 146G>A and tandem transitions − 124_125GG>AA and − 138_139GG>AA.

Conclusions

Telomerase reverse transcriptase promoter mutations are early events in conjunctival neoplasia and could be used for timely diagnosis of conjunctiva tumours. The high frequency of UV-signatures in HIV-positive conjunctiva lesions suggests an additive effect of the virus to UV-related mutagenesis.

TERT

telomerase reverse transcriptase

SCC

squamous cell carcinoma

CIN

conjunctival intraepithelial neoplasia

HIV

human immunodeficiency virus

Background

Squamous cell carcinoma (SCC) of the conjunctiva is a relatively common tumour in subjects infected with the human immunodeficiency virus (HIV) living in the United States or in tropical regions of Africa [1‐6]. In the United States, during the period 1996–2012, the standardised incidence ratio (SIR) for SCC of conjunctiva was 5.56 (CI 95%, 3.44–8.50) among HIV positive people versus the US general population [3]. In sub-Saharan African countries a strong association between conjunctiva SCC and HIV infection was reported since the 1980s. Indeed, the incidence of conjunctiva SCC increased more than tenfold between 1960–1971 and 1995–1997 in Kampala (Uganda) and near tenfold during the period 1991–2004 in Harare, Zimbabwe [7, 8]. More recently, a cross sectional study performed at the Kenyatta Hospital in Kenya showed that conjunctiva SCC has been the leading non-AIDS defining malignancy during the years 2000–2011 among HIV-positive patients [9].

A causal association between oncogenic viruses and conjunctival neoplasia, including human herpesvirus 8 (HHV8) as well as cutaneous and mucosal human papillomaviruses (HPVs), has been extensively searched but the results remained inconclusive [10‐12].

The high prevalence of tandem CC to TT mutations identified in the TP53 gene of conjunctiva SCC DNA was suggestive of the important role played by UV solar radiation in the pathogenesis of such tumour [13, 14]. In addition, UV-related mutations along with hot spot mutations have also been identified in the promoter region of telomerase (TERT) gene in sun-exposed tumours such as melanoma, basal cell carcinoma, non melanoma skin cancer and conjunctiva SCC [15‐18]. Both hot spot and UV-related mutations in TERT promoter region act as oncogenic driver events by creating binding sites for the E-twenty-six (ETS) transcription factors which generally cause a two to fourfold increase in the expression levels of TERT gene [19]. In some tumour types, including hepatocellular carcinoma and follicular thyroid adenoma, TERT promoter mutations are early events in the neoplastic process and they might be useful to monitor tumour development from dysplastic lesions [20, 21].

Very few studies have compared the mutation profile of tumours arising in HIV-positive patients versus those without HIV infection. Gleber-Netto et al. [22] analyzed the nucleotide sequence of 18 genes in HIV-related and non-HIV-related head and neck SCC and showed that among HIV-positive patients the mutations tended to be TpC>T in all mutated genes but especially in TP53. This type of nucleotide change is mainly caused by the activity of APOBEC family cytosine deaminases as host defence against viral infections which also cause nucleotide mutations in human DNA [23, 24].

In this study we have assessed the presence of TERT promoter mutations in HIV-positive and HIV-negative conjunctiva neoplasia cases to identify a possible synergistic effect of HIV on the accumulation of UV-induced mutations. Moreover, we have included in this analysis conjunctival lesions with different degree of malignancy in order to determine how early this genetic event occurs during carcinogenesis. HIV-related cutaneous Kaposi sarcoma (KS) biopsies have been also included in this study in order to verify the eventual effect of HIV status on the occurrence of TERT promoter mutations in lesions developing at body sites not exposed to sun UV radiation.

Methods

Patients

The cohort study comprised conjunctiva neoplasia patients surgically treated at seven countrywide eye clinics in Southern Uganda, within the Ugandan Ruharo Eye Project coordinated by Dr Waddell KM [11]. The histological diagnosis was performed by Prof Lucas SB at the Department of Histopathology, King’s & St Thomas’ School, London, UK. The conjunctiva control tissues were obtained from healthy subjects matched to the cases by sex and age (± 10 years), which were treated for eye injuries or pterygium in the seven eye clinics. Moreover, HIV-related cutaneous African KS cases were also included in this study [25]. All cases and controls were previously characterized in terms of histology, DNA quality, HIV serology, cutaneous and mucosal HPV as well as HHV8 DNA positivity [11, 25, 26]. The study was approved by the Institutional Scientific Board of the Istituto Nazionale Tumori “Fond Pascale”, and is in accordance with the principles of the Declaration of Helsinki.

TERT promoter mutation analysis

Telomerase reverse transcriptase promoter region was amplified using the primer pair hTERT-F (5′-ACGAACGTGGCCAGCGGCAG-3′) and hTERT-R (5′-CTGGCGTCCCTGCACCCTGG-3′), generating a 474 bp fragment covering the rs2853669, rs34233268, rs34764648 and rs35226131 single nucleotide polymorphisms (SNPs) and the hot spot mutations within the TERT promoter region. PCR negative samples were further amplified with the primer set hTERT_short-F (5′-CAGCGCTGCCTGAAACTC-3′) and hTERT_short-R (5′-GTCCTGCCCCTTCACCTT-3′) which amplifies a sequence of 163 bp encompassing the TERT promoter hot spot sites. PCR reactions were performed in 50 μl mixture containing 300 ng of genomic DNA, 10 pmol of each primer, 1.25 Unit of Hot Master Taq DNA Polymerase (5 Prime GmbH, Hamburg, Germany) and 25 μl of PreMix J (Master Amp PCR, Epicentre). DNA was amplified in the Sure Cycler 8800 thermal cycler (Agilent Technologies) with the following steps: an initial denaturation at 94 °C for 3 min, followed by 32 cycles of annealing at 65 °C for 30 s when using hTERT-F/-R primer set or at 53 °C for 30 s when using hTERT_short-F/-R primer set, elongation at 72 °C for 1 min, denaturation at 94 °C for 30 s, and 10 min final elongation at 72 °C. All amplified DNA samples were subjected to automated bidirectional sequencing analysis at Eurofins Genomics, Munich, Germany. Nucleotide sequences were edited using the BioEdit software package (http://jwbrown.mbio.ncsu.edu/BioEdit/bioedit.html).

Statistical analysis

The statistical analyses were performed using Graph Pad Prism Software version 6.00. Two-tailed Χ² test, Χ² test for trend or Fisher’s exact test were used for comparison of categorical data. Differences were considered statistically significant when P values were less than 0.05.

Results

This study included a total of 72 cases of conjunctiva neoplasia, comprising 16 CIN1, 15 CIN2, 17 CIN3 and 24 SCC. Fifty-three conjunctiva non-neoplastic controls and 24 HIV-related KS lesions were also analysed in this study (Table 1). The majority of patients and controls were positive for HIV infection (66.7 and 52.8%, respectively).

Table 1

Distribution of known variables of conjunctival neoplasia cases and controls

	Conjunctiva neoplastic tissues	Conjunctiva control tissue^a	P value
	N = 72 (%)	N = 53 (%)	P value
Sex			0.031
M	29 (40.3)	32 (60.4)
F	43 (59.7)	21 (39.6)
Age			1.000
≤ 30 years	33 (45.8)	24 (45.3)
> 30 years	39 (54.2)	29 (54.7)
TERT promoter mutations			0.0001
Yes	23 (31.9)	1 (1.9)
No	49 (68.1)	52 (98.1)
HIV serology			0.141
Positive	48 (66.7)	28 (52.8)
Negative	24 (33.3)	25 (47.2)

^aThe control group comprises one benign lesion (conjunctiva papilloma) from an HIV-negative subject

Overall, TERT promoter mutations were detected in 23 out of 72 (31.9%) conjunctiva neoplasia cases, in one out of 53 (1.9%) control tissues and were absent in KS lesions (Table 1). The frequency of mutations was found statistically significantly higher in the group of HIV-positive CIN3 and SCC (46.2%) compared to HIV-negative CIN3 and SCC cases (13.3%), P = 0.04, (Table 2). Similarly, a higher mutation rate, although not reaching statistical significance, was observed among HIV-positive CIN1 and CIN2 (31.8%) compared to HIV-negative cases (22.2%). Moreover, the occurrence of TERT promoter mutation in conjunctiva neoplasia was not affected by the HPV or HHV8 infection status.

Table 2

Cutaneous and mucosal HPV and HHV8 infection as well as TERT mutation frequency stratified by conjunctival neoplasia grades and HIV status

	CIN3 + SCC (HIV+)	CIN3 + SCC (HIV−)	CIN1 + CIN2 (HIV+)	CIN1 + CIN2 (HIV−)	Control conjunctiva (HIV+)	Control conjunctiva (HIV−)
	N = 26 (%)	N = 15 (%)	N = 22 (%)	N = 9 (%)	N = 28 (%)	N = 25 (%)
HPV-Pos	4 (15.4)	0 (0.0)	7 (31.8)	2 (22.2)	0 (0.0)	1 (4.0)
HPV-Neg	22 (84.6)	15 (100.0)	15 (68.2)	7 (77.8)	28 (100.0)	24 (96.0)
HHV8-Pos	3 (11.5)	5 (33.3)	5 (22.7)	2 (22.2)	0 (0.0)	1 (4.0)
HHV8-Neg	23 (88.5)	10 (66.7)	17 (77.3)	7 (77.8)	28 (100.0)	24 (96.0)
TERT-Mut^a	12 (46.2)	2 (13.3)	7 (31.8)	2 (22.2)	1 (3.6)	0 (0.0)
TERT-Wt	14 (56.8)	13 (86.7)	15 (68.2)	7 (77.8)	27 (96.4)	25 (100.0)

^aCIN3 + SCC HIV-positive versus HIV-negative, P value 0.04

The most common nucleotide changes were the hot spot mutations − 124G>A (17.4% of all mutated cases) and − 146G>A (21.7%) as well as the UV-related tandem mutations − 124_125GG>AA and − 138_139GG>AA which together added up to 43.5% of all mutated cases. The two hot spots and the UV-related tandem mutations were found mutually exclusive while sporadic changes were detected as additional variations. Particularly, two cases containing the − 124G>A transition also carried a G>A mutation at position − 101 or − 122 from the ATG TERT start site. One sample harbouring the mutation at nt − 146 also contained two additional G>A transitions at nt − 100 and − 149. Tandem mutations − 124_125GG>AA and − 138_139GG>AA were also accompanied by sporadic G>A transitions at nt − 102 in one case and at − 101 and a G>T transversion at position − 125 in another case. Most of the observed changes lead to the creation of putative transcription factor-binding sites, such as the ETS-binding motif and SPI1 or ELK1 binding sites (Table 3). All nucleotide changes were heterozygous with one affected allele (Fig. 1).

Table 3

Pattern of TERT promoter mutations in conjunctival neoplasia and conjunctiva control tissues

TERT mutations^a	Effect^b	CIN3 + SCC	CIN1 + CIN2	Control conjunctiva
TERT mutations^a	Effect^b	N = 41 (%)	N = 31 (%)	N = 53 (%)
− 101G>A	SPI1	3 (7.3)	1 (3.2)	0 (0.0)
− 124G>A^c	ETS	2 (4.9)	2 (6.5)	0 (0.0)
− 124_125GG>AA^d	ELK1	4 (9.8)	1 (3.2)	1 (1.9)
− 138_139GG>AA^e	ETS	3 (7.3)	2 (6.5)	0 (0.0)
− 146G>A^f	ETS	2 (4.9)	3 (9.7)	0 (0.0)
All mutations^g		14 (34.1)	9 (29.0)	1 (1.9)

^aPositions refer to the distance from the ATG start site of TERT gene

^bPutative transcription factors binding sites identified in JASPAR database (http://jaspar.genereg.net)

^cOne sample carried an additional mutation at nt − 101G>A and another at nt − 122G>A (no effect on putative binding sites)

^dOne sample carried an additional mutation at nt − 102G>A (no effect on putative binding sites)

^eOne sample carried two additional mutations at nt − 101G>A and nt − 125G>T with no effect on putative binding sites

^fOne sample carried two additional mutations at nt − 100G>A (no effect on putative binding sites) and nt − 149G>A (creating a putative ETS binding site)

^gΧ² for trend = 16.13, P = 0.00006

Only one HIV-positive case among the conjunctiva control samples harboured a − 124_125GG>AA change suggesting that UV-related mutations may precede the development of conjunctival low grade neoplasia (Table 3). No mutations were identified in TERT promoter region of DNA extracted from HIV-negative conjunctiva controls or HIV-positive cutaneous KS samples.

Several single nucleotide polymorphisms (SNPs) are present within the TERT locus and some have been associated with the risk of cancer. In the present study, the TERT promoter region amplified with hTERT-F and hTERT-R primer set encompassed four SNPs and their allele frequencies have been evaluated in conjunctiva cases and controls. Particularly, a higher frequency of minor alleles (MAF) among cases versus controls was observed for the rs2853669 (− 245 G, MAF = 0.15 and MAF = 0.10, respectively), the rs34233268 (− 218 C, MAF = 3.3 and MAF = 1.9, respectively) and the rs35226131 (− 269 T, MAF = 3.3 and MAF = 1.9, respectively), however such differences did not reach a statistical significance. On the other hand, similar allele distribution has been observed for the rs34764648 (− 354_355, ΔCΔG) with MAF = 5.9 and MAF = 5.7 in cases and controls, respectively.

Discussion

The solar UV radiation exposure is the main cause of the most common skin cancers, such as basal cell carcinoma, cutaneous SCC, cutaneous melanoma and other epithelial tumours such as conjunctiva neoplasia [27, 28]. The frequency of C>T or CC>TT UV-related mutations in TERT promoter region has been found similarly high in basal cell carcinoma (56%), cutaneous SCC (50%), cutaneous melanoma (up to 71%) and conjunctiva neoplasia (43.8%), [16‐18, 29].

The pattern of TERT promoter mutations identified in our Ugandan conjunctiva neoplasia cohort is similar to that previously described in conjunctiva SCC of German patients as well as in melanoma and non-melanoma skin cancers [17, 18, 29, 30]. Interestingly, the occurrence of TERT promoter mutations in 37.5% of CIN1 observed in our results suggests that the UV-induced DNA damage may precede the progression of conjunctiva early lesions to high grade neoplasia.

Several studies demonstrated that HIV infection strongly increases the risk of conjunctiva neoplasia [12]. HIV-related immunosuppression has been demonstrated to play a key role in such association (Holkar et al. [31]; Grulich et al. [32]). In our cohort the frequency of UV-related TERT promoter mutations was significantly higher in HIV-positive compared to HIV-negative conjunctiva neoplasia cases suggesting a synergistic effect of the virus with UV in the accumulation of DNA damages. No biomolecular study has systematically analyzed the effect of HIV on the occurrence of UV-related mutations, however, such phenomenon is supported by epidemiologic studies showing that the incidence of basal cell carcinoma and cutaneous SCC was 2.1-fold higher and 2.6-fold higher, respectively, among HIV-positive patients compared with HIV-negative subjects [33]. In their study, the increased risk of skin cancer was correlated with lower CD4 counts in squamous cell carcinoma but not among basal cell carcinoma among HIV-positive patients suggesting that immunosuppression was only partially responsible for the increased incidence of skin cancer.

A recent report compared the pattern of mutations among HIV-related and non-HIV related head and neck SCC in genes known to be frequently mutated in such tumours and identified a different pattern of nucleotide changes in all mutated genes including TP53 [22]. Particularly, they observed an enrichment of C>T changes in the HIV-infected cases likely caused by the cytosine deamination [34]. We have observed a high rate of single C>T or tandem CC>TT changes in HIV-related conjunctiva lesions but not in HIV-related Kaposi sarcoma suggesting a synergistic effect of UV exposure and HIV infection but not a direct effect of HIV in not UV-related cancers such as Kaposi sarcoma.

The hot spot nucleotide changes − 124G>A and − 146G>A in TERT promoter have been detected at high frequency in cancers of internal organs, such as bladder cancer, hepatocellular carcinoma, thyroid cancer, and gliomas [15, 35, 36]. In contrast, tandem mutations CC>TT are related to the UV mutagenic activity and very rarely identified in tumours of internal organs [13, 29, 35, 35‐39]. In our study CC>TT substitutions in TERT promoter were very frequent in accordance with their overall frequency in other UV-related tumours [16, 40].

TERT promoter mutations create de novo binding motifs for the ETS (E-twenty-six) family or TCF (ternary complex factor) subfamily of transcription factors and increase the expression of TERT by twofold to fourfold [18]. This increased telomerase expression enables tumours to maintain their telomere length and continuously proliferate without becoming apoptotic or senescent due to genetic instability [41, 42].

Several SNPs have been analyzed in conjunctiva samples, including rs2853669, rs34233268, rs34764648 and rs35226131, but no significant differences have been noted on the minor allele frequency distribution among cases and controls. However, the limited number of samples insufficient to perform a significant statistic may have hindered the possibility to associate specific SNPs with susceptibility to conjunctiva neoplasia.

Conclusion

In conclusion, we observed that HIV infection, a major risk factor for development of conjunctiva neoplasia, significantly contributes to the accumulation of UV-related mutations in TERT promoter. Both hot spot mutations and UV-related variations are frequently identified in low grade conjunctiva lesions (CIN and CIN2) as well as in high grade lesions (CIN3) and invasive carcinoma. More studies are needed to understand the molecular mechanisms underlying this previous unknown phenomenon and to determine whether these genetic traits are useful for early detection of conjunctiva progressing lesions.

Authors’ contributions

MLT designed the research project, supervised all experiments and wrote the manuscript; FMB obtained the grant and supervised the project. NS performed the experimental analysis; LB performed the statistical analysis. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to Dr. Waddell KM, coordinator of the Ugandan Ruharo Eye Project, for patients enrolment and to Prof Lucas SB at the Department of Histopathology, King’s & St Thomas’ School in London (UK) for the histological analysis.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Authors can confirm that all relevant data are included in the article and materials are available on request from the authors.

Not applicable.

This study was approved by the Institutional Scientific Board and is in accordance with the principles of the Declaration of Helsinki.

Funding

This project and the publication cost was supported by the research grant Ricerca Corrente N. 2611892 from the Ministero della Salute.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Gichuhi S, Sagoo MS, Weiss HA, Burton MJ. Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health. 2013;18:1424–43.CrossRefPubMedPubMedCentral

Guech-Ongey M, Engels EA, Goedert JJ, Biggar RJ, Mbulaiteye SM. Elevated risk for squamous cell carcinoma of the conjunctiva among adults with AIDS in the United States. Int J Cancer. 2008;122:2590–3.CrossRefPubMed

Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4:e495–504.CrossRefPubMed

Waddell KM, Lewallen S, Lucas SB, Tenyi-Agaba C, Herrington CS, Liomba G. Carcinoma of the conjunctiva and HIV infection in Uganda and Malawi. Br J Ophthalmol. 1996;80:503–8.CrossRefPubMedPubMedCentral

Mbulaiteye SM, Bhatia K, Adebamowo C, Sasco AJ. HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data. Infect Agent Cancer. 2011;6:16.CrossRefPubMedPubMedCentral

Karolo-Anthony SN, Maso LD, Igbinoba F, Mbulaiteye SM, Adebamowo CA. Cancer burden among HIV-positive persons in Nigeria: preliminary findings from the Nigerian AIDS-cancer match study. Infect Agent Cancer. 2014;9:1.CrossRef

Wabinga HR, Nambooze S, Amulen PM, Okello C, Mbus L, Parkin DM. Trends in the incidence of cancer in Kampala, Uganda 1991–2010. Int J Cancer. 2014;135:432–9.CrossRefPubMed

Chokunonga E, Borok MZ, Chirenje ZM, Nyakabau AM, Parkin DM. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. Int J Cancer. 2013;133:721–9.CrossRefPubMed

Rogena EA, Simbiri KO, De FG, Leoncini L, Ayers L, Nyagol J. A review of the pattern of AIDS defining, HIV associated neoplasms and premalignant lesions diagnosed from 2000–2011 at Kenyatta National Hospital, Kenya. Infect Agent Cancer. 2015;10:28. https://doi.org/10.1186/s13027-015-0021-1 (eCollection; %2015.:28-0021).CrossRefPubMedPubMedCentral

10.

Starita N, Annunziata C, Waddell KM, Buonaguro L, Buonaguro FM, Tornesello ML. Identification of human herpesvirus 8 sequences in conjunctiva intraepithelial neoplasia and squamous cell carcinoma of Ugandan patients. Biomed Res Int. 2015;2015:801353. https://doi.org/10.1155/2015/801353 (Epub;%2015 Oct 5.:801353).CrossRefPubMedPubMedCentral

11.

Tornesello ML, Duraturo ML, Waddell KM, Biryahwaho B, Downing R, Balinandi S, Lucas SB, Buonaguro L, Buonaguro FM. Evaluating the role of human papillomaviruses in conjunctival neoplasia. Br J Cancer. 2006;94:446–9.CrossRefPubMedPubMedCentral

12.

Carreira H, Coutinho F, Carrilho C, Lunet N. HIV and HPV infections and ocular surface squamous neoplasia: systematic review and meta-analysis. Br J Cancer. 2013;109:1981–8.CrossRefPubMedPubMedCentral

13.

Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88:10124–8.CrossRefPubMedPubMedCentral

14.

Ateenyi-Agaba C, Dai M, Le CF, Katongole-Mbidde E, Smet A, Tommasino M, Franceschi S, Hainaut P, Weiderpass E. TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis. Mutagenesis. 2004;19:399–401.CrossRefPubMed

15.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih I, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110:6021–6.CrossRefPubMedPubMedCentral

16.

Griewank KG, Murali R, Schilling B, Schimming T, Moller I, Moll I, Schwamborn M, Sucker A, Zimmer L, Schadendorf D, Hillen U. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS ONE. 2013;8:e80354.CrossRefPubMedPubMedCentral

17.

Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959–61.CrossRefPubMed

18.

Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957–9.CrossRefPubMedPubMedCentral

19.

Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Shibui S, Ichimura K. TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol. 2013;126:939–41.CrossRefPubMed

20.

Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget. 2016;7:54253–62.CrossRefPubMedPubMedCentral

21.

Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Hoog A, Larsson C, Xu D. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014;120:2965–79.CrossRefPubMed

22.

Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN Jr, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer Cytopathol. 2018;124:84–94.CrossRef

23.

Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494:366–70.CrossRefPubMedPubMedCentral

24.

Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014;7:1833–41.CrossRefPubMed

25.

Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Katongole-Mbidde E, Loquercio G, Buonaguro L, Buonaguro FM. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi’s sarcoma lesions during pre-AIDS and AIDS era. Virology. 2010;398:280–9.CrossRefPubMed

26.

Tornesello ML, Waddell KM, Duraturo ML, Biryahwaho B, Downing R, Lucas SB, Giani U, Buonaguro L, Buonaguro FM. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detect Prev. 2005;29:501–8.CrossRefPubMed

27.

Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer—the role of sunlight. Adv Exp Med Biol. 2008;624:89–103. https://doi.org/10.1007/978-0-387-77574-6_8.:89-103.CrossRefPubMed

28.

Newton R. A review of the aetiology of squamous cell carcinoma of the conjunctiva. Br J Cancer. 1996;74:1511–3.CrossRefPubMedPubMedCentral

29.

Scholz SL, Thomasen H, Reis H, Moller I, Darawsha R, Muller B, Dekowski D, Sucker A, Schilling B, Schadendorf D, Steuhl KP, Paschen A, Westekemper H, Meller D, Griewank KG. Frequent TERT promoter mutations in ocular surface squamous neoplasia. Invest Ophthalmol Vis Sci. 2015;56:5854–61.CrossRefPubMed

30.

Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014;27:516–23.CrossRefPubMed

31.

Holkar S, Mudhar HS, Jain A, Gupta M, Rogstad KE, Parsons MA, Singh AD, Rennie IG: Regression of invasive conjunctival squamous carcinoma in an HIV-positive patient on antiretroviral therapy. Int J STD AIDS 2005;16:782-783.

32.

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67

33.

Silverberg MJ, Leyden W, Warton EM, Quesenberry CP Jr, Engels EA, Asgari MM. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105:350–60.CrossRefPubMedPubMedCentral

34.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.CrossRefPubMedPubMedCentral

35.

Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98:E1562–6.CrossRefPubMedPubMedCentral

36.

Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.CrossRefPubMed

37.

Populo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimaraes I, Manuel LJ, Sobrinho-Simoes M, Soares P. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol. 2014;134:2251–7.CrossRefPubMed

38.

Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 2013;110:17426–31.CrossRefPubMedPubMedCentral

39.

Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;17:45–52.CrossRefPubMed

40.

Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014;5:3401.CrossRefPubMed

41.

Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 2005;579:859–62.CrossRefPubMed

42.

Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell. 2013;152:390–3.CrossRefPubMed

Titel: Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia
verfasst von: Noemy Starita
Luigi Buonaguro
Franco M. Buonaguro
Maria Lina Tornesello
Publikationsdatum: 01.12.2018
Verlag: BioMed Central
Erschienen in: Journal of Translational Medicine / Ausgabe 1/2018
Elektronische ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-018-1456-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Background

Methods

Patients

TERT promoter mutation analysis

Statistical analysis

Results

Discussion

Conclusion

Authors’ contributions

Acknowledgements

Competing interests

Availability of data and materials

Consent for publication

Ethics approval and consent to participate

Funding

Publisher’s Note

Weitere Artikel der Ausgabe 1/2018

Systematic analysis of lncRNA–miRNA–mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

NovelmiRNA-25 inhibits AMPD2 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and represents a promising novel biomarker

HNA-3a and HNA-3b antigens among 9 ethnic populations and the Han population in Southwest China

Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination

Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Update Innere Medizin